Evotec SE (BIT:1EVT)

Market Cap	990.06M -5.5%
Revenue (ttm)	788.37M -1.1%
Net Income	-103.52M
EPS	-0.58
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2,913
Open	n/a
Previous Close	5.54
Day's Range	n/a
52-Week Range	4.06 - 8.39
Beta	n/a
RSI	68.62
Earnings Date	Apr 8, 2026

About Evotec SE

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and c...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 4,467
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1EVT

Financial Performance

In 2025, Evotec SE's revenue was 788.37 million, a decrease of -1.08% compared to the previous year's 796.97 million. Losses were -103.52 million, -47.21% less than in 2024.